APPLICATION
ANDA071170
TYPE
ANDA
ORIGINAL APPROVAL
1988-06-16
LATEST ACTION
2021-07-06
ROUTE
PERINEURAL, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription
Products
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINEPrescription
BUPIVACAINE HYDROCHLORIDE 0.5%, EPINEPHRINE 0.005MG/ML · INJECTABLE · INJECTION
Approval history
2021-07-06Labeling · Supplement 39 · standardAP
2020-12-09Labeling · Supplement 37 · standardAP
2015-08-20Labeling · Supplement 29 · standardAP
2015-08-20Labeling · Supplement 31 · standardAP
2010-04-27Labeling · Supplement 21AP
2002-12-20Manufacturing (CMC) · Supplement 12AP
1999-11-22Labeling · Supplement 11AP
1998-05-28Manufacturing (CMC) · Supplement 10AP
1998-05-28Manufacturing (CMC) · Supplement 8AP
1997-09-26Manufacturing (CMC) · Supplement 9AP
1997-09-26Manufacturing (CMC) · Supplement 7AP
1991-02-21Manufacturing (CMC) · Supplement 3AP
1991-02-21Manufacturing (CMC) · Supplement 1AP
1990-10-03Labeling · Supplement 5AP
1990-05-04Labeling · Supplement 4AP
1988-06-16OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.